"We're very excited to welcome John to ZenBio, he adds a great deal of expertise in cell therapy, tissue engineering, and preclinical development that will be an asset for us as the company continues to move forward", said Peter Pieraccini, ZenBio's CEO.
Prior to joining Tengion 7 years ago, Dr. Ludlow spent 5 years directing cell therapy programs at Incara Pharmaceuticals and Vesta Therapeutics. Dr. Ludlow began his career conducting tumor suppressor research as an Associate Professor at the University of Rochester Cancer Center. He earned his Ph.D. in Microbiology at Kansas State University, his M.S. in Microbiology at Idaho State University and his B.S. at Utica College.
About ZenBio, Inc.
ZenBio, Inc., a privately held biotechnology company, is a leading provider of research tools for the study of human metabolic disease. Founded in 1995, the company performs contract research for major pharmaceutical and biotechnology companies around the world. ZenBio pioneered tissue engineering with adult adipose-derived stem cells and is currently investigating the role obesity plays in the development and onset of metabolic disease. Its mission is to provide the highest quality cells, reagents and contract services to the biomedical research community; to develop and commercialize research tools; and to leverage its expertise in this field as a contract research organization. www.zenbio.com